HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Crypto · News reference
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
Dutch Bros, SoundHoundAI, Kohl's and Ondas are among the top ten most-heavily shorted stocks in the market right now.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIaInitial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent
Dutch Bros Has Lost a Third of Its Value in 2026. Is It Time to Buy?
Dutch Bros stock has declined 33% year-to-date despite strong business fundamentals. The coffee chain continues to beat analyst expectations with 58% sales growth over three years, 62% store expansion to 1,225 locations, and tripled free cash flow. The company's drive-through model and expansion plans targeting 2,029 stores by 2029 position it well for long-term growth, suggesting the market decline presents a buying opportunity.
Morgan Stanley Maintains Overweight on Dutch Bros, Lowers Price Target to $71
Stephens & Co. Maintains Overweight on Dutch Bros, Lowers Price Target to $65